Abbott and Neurocrine Biosciences, Inc. announced they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently...
An already promising initiative to assist start-up firms that commercialize technologies associated with the Quality of Life Technology (QoLT) Center is now expanding thanks to a three-year, $1.5 million Innovation Award from the National Science Foundation's (NSF) Division of Engineering...